Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK, PD, and Safety of Vamifeport IR and PR Formulations in Healthy Adults
NCT06726863Phase 1Completed
- Sponsor
- CSL Limited
- Start
- Nov 2024
- Primary completion
- Jan 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of vamifeport in beta thalassemia and sickle cell disease (SCD) (7 arms), sponsored by CSL Limited. Primary endpoints: Plasma concentration-time course profiles of vamifeport at Day 16, Maximum plasma concentration at Day 16 and 15 more. Started Nov 2024; status: completed.
02
Drugs
vamifeport
03
Conditions
beta thalassemiasickle cell disease (SCD)
Beyond the preview
Go deeper on NCT06726863.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06726863.